Condition: Advanced Refractory Solid Tumors · EGFR Gene Overexpression · Sponsor: Tianjin Medical University Second Hospital
This phase II trial evaluates the combination of Becotatug Vedotin (MRG003), an EGFR-targeting ADC, and Pucotenlimab (HX008), a PD-1 inhibitor, in patients with high EGFR expressing advanced refractory solid tumors. The study is designed to assess clinical efficacy and safety, building on a strong synergistic rationale and promising early-phase data.
This description comes directly from the study's public registry record.
Haitao Wang, Ph.D. · +86-022-88321190 · peterrock2000@126.com
Lili Wang, Ph.D. · +86-022-88321185 · wangliliaigang@163.com
Always discuss trial participation with your own doctor first.
| Tianjin Medical Unversity Second Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07712029